BOL

FDA has approved Viiv Healthcare’s integrase inhibitor Tivicay® (dolutegravir) 50-mg tablets, for use with other antiretroviral agents in treating HIV-1 infection. ViiV Healthcare is an HIV therapeutics company established in 2009 by GlaxoSmithKline and Pfizer.

Tivicay is indicated for infected adults, both treatment-naive and treatment-experienced, including those treated with other integrase strand transfer inhibitors; as well as for children aged 12 years and older weighing at least 40 kg (approx. 88 lbs). The drug - which was used without a pharmacokinetic boosting agent - interferes with one of the enzymes necessary for HIV to multiply, and can be taken with or without food and at any time of day.

http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm364869.htm